CERENIS THERAPEUTICS HOLDING Inactive Instrument
Cerenis Therapeutics Holding Stock Euronext Paris
Equities
FR0012616852
Biotechnology & Medical Research
| Sales 2023 | 4.6M 4.9M | Sales 2024 * | 4.6M 4.9M | Capitalization | 34.59M 36.81M |
|---|---|---|---|---|---|
| Net income 2023 | -3M -3.19M | Net income 2024 * | -6M -6.39M | EV / Sales 2023 | 9.02 x |
| Net cash position 2023 * | 100K 106K | Net cash position 2024 * | 3.4M 3.62M | EV / Sales 2024 * | 6.78 x |
| P/E ratio 2023 * |
-7.67
x | P/E ratio 2024 * |
-7.16
x | Employees | - |
| Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 77.63% |
More Fundamentals
* Assessed data
More news
More press releases
More news
| Managers | Title | Age | Since |
|---|---|---|---|
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
| Director of Finance/CFO | - | 08-04-30 | |
Renee Benghozi
CTO | Chief Tech/Sci/R&D Officer | - | 15-02-08 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Olivier Martinez
BRD | Director/Board Member | 54 | - |
Christian Chavy
BRD | Director/Board Member | 75 | 15-02-05 |
Cyrille Tupin
CEO | Chief Executive Officer | 48 | 06-12-31 |
ABIONYX Pharma SA is specialized in research & development into HDL therapies (High Density lipoproteins) intended for the treatment of cardiovascular and metabolic disorders. HDLs, also known as good cholesterol, are fat and protein complexes that contribute to the transportation of cholesterol from the body's tissues to the liver and are linked to a decrease in the risk of atherosclerosis and coronary diseases.
At the end of 2022, the company boasted a portfolio of 3 products in clinical development.
Calendar
2024-05-15
- Q1 2024 Sales and Revenue Release
| 1st Jan change | Capi. | |
|---|---|---|
| -3.30% | 102B | |
| +1.79% | 96.84B | |
| -0.44% | 21.48B | |
| -18.35% | 20.82B | |
| -7.45% | 18.6B | |
| -40.31% | 16.81B | |
| -26.84% | 13.78B | |
| +0.59% | 13.4B | |
| +20.86% | 11.06B |
